Rocket Pharmaceuticals (RCKT) PT Lowered to $7 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts RCKT Hot Sheet
Price: $2.29 -0.87%
Rating Summary:
16 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
16 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Leerink Partners analyst Mani Foroohar lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $7.00 (from $9.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- Kotak Mahindra Bank Ltd. (KMB:IN) PT Raised to INR492 at JPMorgan
- Jefferies Upgrades Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) to Hold
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
